Faeth Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Faeth Therapeutics, Inc. (FTH) reported Other Comprehensive Income (Loss), Net of Tax of -$39.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$39.00K.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$25.00K, a 457.14% decline year-over-year.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $4.00K.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $8.00K, a 92.52% decline year-over-year.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $14.00K, a 92.86% decline from fiscal 2024.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $196.00K, a 75.35% decline from fiscal 2023.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $795.00K.
- Faeth Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$671.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.00K 10-Q · filed 2026-08-04 | -$64.00K 10-Q · filed 2026-08-04 | -$60.00K derived: sum of 3 quarters · filed 2026-08-04 | -$52.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$25.00K 10-Q · filed 2026-05-15 | -$21.00K derived: sum of 2 quarters · filed 2026-05-15 | -$13.00K derived: sum of 3 quarters · filed 2026-05-15 | -$18.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $12.00K derived: sum of 2 quarters · filed 2026-03-30 | $7.00K derived: sum of 3 quarters · filed 2026-08-04 | $14.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.00K 10-Q · filed 2025-11-14 | $3.00K derived: sum of 2 quarters · filed 2026-08-04 | $10.00K 10-Q · filed 2025-11-14 | -$17.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$5.00K 10-Q · filed 2026-08-04 | $2.00K 10-Q · filed 2026-08-04 | -$25.00K derived: sum of 3 quarters · filed 2026-08-04 | $82.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $7.00K 10-Q · filed 2026-05-15 | -$20.00K derived: sum of 2 quarters · filed 2026-05-15 | $87.00K derived: sum of 3 quarters · filed 2026-05-15 | $131.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $80.00K derived: sum of 2 quarters · filed 2026-03-30 | $124.00K derived: sum of 3 quarters · filed 2026-03-30 | $196.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $107.00K 10-Q · filed 2025-11-14 | $151.00K derived: sum of 2 quarters · filed 2025-11-14 | $223.00K 10-Q · filed 2025-11-14 | $416.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-05 | $116.00K 10-Q · filed 2025-08-05 | $309.00K derived: sum of 3 quarters · filed 2025-08-05 | $456.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $72.00K 10-Q · filed 2025-05-06 | $265.00K derived: sum of 2 quarters · filed 2025-05-06 | $412.00K derived: sum of 3 quarters · filed 2025-05-06 | $686.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $340.00K derived: sum of 2 quarters · filed 2025-03-28 | $614.00K derived: sum of 3 quarters · filed 2025-03-28 | $795.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $147.00K 10-Q · filed 2024-11-14 | $421.00K derived: sum of 2 quarters · filed 2024-11-14 | $602.00K 10-Q · filed 2024-11-14 | $803.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $274.00K 10-Q · filed 2024-08-06 | $455.00K 10-Q · filed 2024-08-06 | $656.00K derived: sum of 3 quarters · filed 2024-08-06 | $663.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $181.00K 10-Q · filed 2024-05-09 | $382.00K derived: sum of 2 quarters · filed 2024-05-09 | $389.00K derived: sum of 3 quarters · filed 2024-05-09 | $76.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $208.00K derived: sum of 2 quarters · filed 2024-02-29 | -$105.00K derived: sum of 3 quarters · filed 2024-02-29 | -$671.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $7.00K 10-Q · filed 2023-11-07 | -$306.00K derived: sum of 2 quarters · filed 2023-11-07 | -$872.00K 10-Q · filed 2023-11-07 | -$1.14M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$313.00K 10-Q · filed 2023-08-03 | -$879.00K 10-Q · filed 2023-08-03 | -$1.14M derived: sum of 3 quarters · filed 2023-08-03 | -$1.11M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$566.00K 10-Q · filed 2023-05-09 | -$830.00K derived: sum of 2 quarters · filed 2023-05-09 | -$798.00K derived: sum of 3 quarters · filed 2023-05-09 | -$899.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$232.00K derived: sum of 2 quarters · filed 2023-03-29 | -$333.00K derived: sum of 3 quarters · filed 2023-03-29 | -$333.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $32.00K 10-Q · filed 2022-11-08 | -$69.00K derived: sum of 2 quarters · filed 2022-11-08 | -$69.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$101.00K 10-Q · filed 2022-08-09 | -$101.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |